Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 26, 2026
SPMD: Is +15% to $75 Within Reach for This Mid-Cap ETF?

SPMD: Is +15% to $75 Within Reach for This Mid-Cap ETF?

Key Takeaways

  • SPMD tracks the S&P MidCap 400 Index and has recently traded in the mid-$60s within a 52-week range of about $54 to $69.
  • A $75 price target implies roughly a 15% advance from current levels and falls just below the most optimistic aggregate analyst forecasts for the fund’s holdings.
  • Key bullish elements include the ongoing valuation discount for mid-caps relative to large-caps and the fund’s tilt toward industrials, financials, and technology.
  • Primary challenges center on mid-cap underperformance versus mega-cap stocks and the fund’s cyclical exposure to economic shifts.
  • The prior high near $69 represents the main resistance to overcome, while support has held in the mid-to-high $50s.
  • Reaching $75 appears plausible but would probably need stronger mid-cap earnings growth and a sustained rotation away from the largest stocks.

Why the $75 Target Stands Out

The State Street SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) follows the S&P MidCap 400 Index, a market-cap-weighted benchmark covering roughly 400 mid-sized U.S. companies. After approaching its 52-week high near $69, the fund has pulled back into the mid-$60s, prompting questions about whether a move toward the round $75 level is realistic.

That $75 objective is neither trivial nor distant. It sits about 15% above recent prices, above the prior peak yet aligned with more bullish analyst projections based on underlying holdings. This makes it a concrete, frequently referenced goal rather than an immediate expectation.

SPMD at a Glance and Its Current Standing

SPMD belongs to State Street’s low-cost “SPDR Portfolio” lineup, introduced in 2017 as a more affordable option than the older SPDR S&P MidCap 400 ETF Trust. Its 0.03% expense ratio ranks it among the cheapest vehicles for broad mid-cap exposure, competing with offerings from Vanguard, Schwab, and iShares. The fund manages more than $15 billion in assets and delivers a dividend yield of approximately 1.3%.

Unlike large-cap indexes heavy with a few mega-cap technology names, SPMD’s sector allocation favors industrials, financials, consumer discretionary, and information technology. I also checked this using Tickeron’s AI Screener to see how the fund’s composition compares with peers. This mix gives the ETF a more cyclical profile, so its results tend to align closely with the overall domestic economy rather than a narrow group of growth leaders.

Key Holdings and Sector Influences

With hundreds of positions, no single stock drives SPMD’s performance. Leading holdings include Interactive Brokers Group (IBKR), EMCOR Group (EME), Watsco (WSO), RB Global (RBA), and Fidelity National Financial (FNF), each typically representing well under 1% of assets.

This diversification means progress toward $75 hinges on the collective earnings strength of the mid-cap segment. Commentary has noted that SPMD trades at a notable valuation discount to the S&P 500, reflecting slower recent earnings growth yet offering room for expansion if mid-cap profitability improves. A rotation into industrials and financials, or wider mid-cap breadth, would directly support higher prices for the fund.

Factors That Could Push SPMD Higher

Several elements could support a move toward $75. The valuation gap between mid-caps and large-caps remains historically wide, a pattern that has often preceded periods of mid-cap outperformance. Lower interest rates generally help mid-sized firms, which tend to carry more debt and depend more on financing for expansion. Faster earnings growth across the holdings would also support a re-rating of the index.

Mean reversion plays a role as well. A sustained break above the prior high near $69 would clear the key resistance and could draw momentum and institutional flows, reinforcing the uptrend. From what I see, Tickeron’s AI Trend Prediction Engine offers one way to monitor these shifts in real time.

Potential Roadblocks Ahead

The most immediate hurdle remains persistent mid-cap underperformance. In recent years, the largest technology companies have accounted for most market gains, and SPMD’s smaller technology weighting has limited its participation. Continued mega-cap dominance could keep the fund from reaching new highs.

Macro risks also weigh on the cyclical profile. Tariffs, inflation, a softer labor market, or weaker consumer demand would likely pressure mid-cap earnings more than large-cap ones, potentially leaving SPMD range-bound below $69. A broader market decline could push the fund back toward the support zone in the mid-to-high $50s before any advance to $75 becomes feasible.

Price Targets and Technical Levels

As an ETF, SPMD does not carry standalone analyst ratings. Instead, firms aggregate price targets from the underlying stocks. Those calculations point to an average implied 12-month target in the mid-to-high $60s, with the upper end of forecasts reaching the upper $70s. This indicates that while the average expectation falls short of $75, the more optimistic projections already contemplate that level.

Technically, the $69 area—the recent 52-week high—remains the critical resistance. A decisive move above it would open the path to psychological targets at $70 and then $75. Support has consistently appeared in the mid-to-high $50s, providing a clear floor beneath current prices.

Final Assessment

A move to $75 for SPMD is ambitious yet within the realm of possibility. The fund trades roughly 15% below that mark, and the most bullish analyst-derived targets for its holdings already approach the upper $70s. The strongest arguments rest on the valuation discount applied to mid-caps, the fund’s low-cost structure, and its exposure to cyclical sectors that could benefit from a broadening rally.

The main risks are straightforward. SPMD has lagged large-cap benchmarks in recent years, and its cyclical tilt leaves it exposed to any economic slowdown. Investors should watch whether the fund clears the $69 resistance, whether mid-cap earnings growth accelerates, and whether market leadership shifts away from mega-cap technology. Until those conditions align, $75 stays a plausible objective rather than a near-term certainty.

AI Daily Buy/Sell Signals

In my own research process, I’ve found Tickeron’s AI Daily Buy/Sell Signals useful for monitoring SPMD and other ETFs. The tool applies artificial intelligence to review technical behavior and market conditions, generating Buy, Sell, or Hold signals that help track opportunities and emerging trends without constant manual chart review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SPMD

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SPMD in downward trend: price dove below 50-day moving average on August 28, 2026

SPMD moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPMD as a result. In 69 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for SPMD turned negative on August 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 35 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

The 10-day moving average for SPMD crossed bearishly below the 50-day moving average on September 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for SPMD entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SPMD's RSI Indicator exited the oversold zone, 26 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 52 cases where SPMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPMD advanced for three days, in 268 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

SPMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are Twilio (NYSE:TWLO), Illumina (NASDAQ:ILMN), Okta (NASDAQ:OKTA), Roku (NASDAQ:ROKU), Nutanix (NASDAQ:NTNX), Lattice Semiconductor Corp (NASDAQ:LSCC), MasTec (NYSE:MTZ), Exelixis (NASDAQ:EXEL), Five Below (NASDAQ:FIVE), GameStop Corp (NYSE:GME).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P MidCap 400 Index. Under normal market conditions, the fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index is designed to measure the performance of the mid-capitalization segment of the U.S. equity market.

Market Cap

The average market capitalization across the State Street SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) ETF is 9.22B. The market cap for tickers in the group ranges from 1.69B to 42.36B. TWLO holds the highest valuation in this group at 42.36B. The lowest valued company is SAM at 1.69B.

High and low price notable news

The average weekly price growth across all stocks in the State Street SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) ETF was 0%. For the same ETF, the average monthly price growth was -4%, and the average quarterly price growth was 11%. VICR experienced the highest price growth at 27%, while PLNT experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the State Street SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) ETF was -49%. For the same stocks of the ETF, the average monthly volume growth was 4% and the average quarterly volume growth was -0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 50
Price Growth Rating: 55
SMR Rating: 55
Profit Risk Rating: 67
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
SPMD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category MidCapBlend

Category
Mid-Cap Blend
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.